Phreesia ($PHR) Network Solutions Revenue Guidance Case

Investors can submit applications for the lead plaintiff role.

D. Delaware

Court

1:26-cv-00556

Case number

05/07/2025

Class period Start

03/29/2026

Class period End

07/12/2026

Lead Plaintiff motion deadline

$PHR investors filed a claim against Phreesia for allegedly overstating its growth outlook while hiding weaker pharmaceutical marketing commitments in its Network Solutions segment.
After Phreesia lowered its fiscal 2027 revenue guidance, $PHR fell 26.6% on March 31, 2026.
$PHR investors can join this case to be notified about potential recovery.
Case Details:

Between May 8, 2025 and March 30, 2026, Phreesia told investors it was positioned for continued growth and improving profitability. Executives emphasized strong performance, continued expansion of Network Solutions, growth opportunities from new products, and expected contributions from the AccessOne acquisition.

However, during this period, investors allege Phreesia had slowing demand and reduced visibility in important revenue streams, especially pharmaceutical marketing commitments in Network Solutions. Phreesia allegedly failed to disclose that some pharmaceutical customers were committing less marketing spend than expected. Network Solutions revenue forecasts were becoming less reliable, especially for the second half of fiscal 2027, and Phreesia’s fiscal 2027 revenue target was at risk.

Then, on March 30, 2026, the company reported Q4 and fiscal 2026 results and lowered fiscal 2027 revenue guidance to $510 million to $520 million from its prior range of $545 million to $559 million.

$PHR fell 26.6%, closing at $8.38. Additional details included shorter visibility into pharmaceutical manufacturer spending commitments and lower expected second-half fiscal 2027 Network Solutions spending.

By March 31, 2026, shares had dropped to $8.38, representing a total decline of 26.6% over the correction period.

Based on these events, $PHR investors filed a claim against Phreesia, alleging the company:
It overstated the durability of Network Solutions growth.
It minimized weaker pharmaceutical marketing commitments and reduced revenue visibility.
It caused investors to reassess Phreesia when the company cut fiscal 2027 guidance.
Investors argue Phreesia misled the market about Network Solutions demand and its fiscal 2027 growth outlook, causing losses when the truth emerged.

Case Type

US Securities Class Action

Case Status

Lead Plaintiff Submission

Alleged Offence

Misleading Statements,

Fraud,

Failure to Disclose,

Omissions

Suspected Party

Management

Security Type

Stocks

Trade Direction

Long

Shock Event Date

03/29/2026

Filing date

05/12/2026

Lead Plaintiff Deadline

07/12/2026

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.